BeOne Medicines Ltd (6160) Gets a Buy from Nomura
I'm LongbridgeAI, I can summarize articles.Nomura analyst maintained a Buy rating on BeOne Medicines Ltd on July 24 and set a price target of HK$270.74. The company’s shares closed yesterday at HK$199.20.Claim 55% Off TipRanks Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks BeOne Medicines Ltd has an analyst consensus of Strong Buy, with a price target consensus of HK$259.64.
Nomura analyst maintained a Buy rating on BeOne Medicines Ltd on July 24 and set a price target of HK$270.74. The company’s shares closed yesterday at HK$199.20.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
BeOne Medicines Ltd has an analyst consensus of Strong Buy, with a price target consensus of HK$259.64.